Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesInflaRx N.V.

InflaRx N.V.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.31 USD -0.04 ( 3.32%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1070707
Market Cap
295.47M

Momentum Score

…

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.17
Low
1.32
High
52 Week Price Range
0.80
Low
2.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

InflaRx N.V. is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies that inhibit complement component C5a for severe inflammatory diseases. Its long-term growth may be supported by positive late-stage clinical outcomes, regulatory approvals across indications, and potential licensing or commercialization partnerships that could benefit investors seeking exposure to targeted anti-inflammatory therapeutics.

Key investment risks include high clinical and regulatory execution risk, lack of commercial revenue requiring additional financing, concentrated single-asset exposure and significant competition from larger immunology companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.35
Dividend Yield
-
Revenue TTM
-0.01M
Revenue Per Share
-
Gross Profit TTM
-4.87M
Debt / Equity
0.02
ROE
-38.52%
Net Debt
-15.12M
ROCE
-107.97%
Diluted EPS TTM
-0.58

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -45.62M -46.06M -42.67M -29.48M -45.63M
Net income -45.63M -46.06M -42.67M -27.04M -45.65M
Selling general administrative 15.52M 15.29M 14.22M 14.87M 11.98M
Selling and marketing expenses 2.05M 4.04M 1.91M - -
Gross profit -7.24M -3.15M -0.47M - -
Reconciled depreciation 0.42M 0.49M 0.58M 0.60M 0.67M
Ebit -45.58M -46.04M -42.63M -32.24M -47.63M
Ebitda -45.16M -45.55M -42.06M -31.29M -46.90M
Depreciation and amortization 0.42M 0.49M 0.57M 0.95M 0.73M
Operating income -48.26M -52.91M -44.59M -32.24M -47.63M
Other operating expenses 48.29M 53.07M 44.66M 32.24M 47.63M
Interest expense 0.04M 0.02M 0.04M 0.05M 0.02M
Tax provision 0.01M 0.01M 0.00M 0.00M 0.00M
Interest income 1.85M 3.20M 3.03M 0.61M 0.11M
Net interest income 7.49M 3.28M 3.35M 0.31M 0.04M
Income tax expense 0.01M 0.01M -0.00M -2.44M 0.02M
Total revenue 0.03M 0.17M 0.06M 0.00M 0.00M
Total operating expenses 41.02M 49.75M 44.13M 32.24M 47.63M
Cost of revenue 7.27M 3.32M 0.53M - -
Total other income expense net 2.64M 6.85M 1.93M 2.75M 2.00M
Net income from continuing ops -45.63M -46.06M -34.76M -29.48M -45.63M
Net income applicable to common shares - - - - -45.63M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 55.19M 76.02M 120.31M 102.40M 125.14M
Intangible assets 0.04M 0.01M 0.07M 0.14M 0.24M
Other current assets 5.75M 46.38M 3.95M 14.17M 10.98M
Total liab 13.65M 14.60M 17.64M 14.05M 19.86M
Total stockholder equity 41.54M 61.42M 102.67M 88.35M 105.28M
Other current liab 7.32M 10.35M 11.38M 1.46M 8.44M
Common stock 8.67M 7.12M 7.07M 5.36M 5.30M
Capital stock 8.68M 7.12M 7.07M 5.36M 5.30M
Retained earnings -377.67M -332.19M -286.36M -243.46M -213.98M
Other liab - - - - 0.04M
Other assets - - 0.00M - 0.34M
Cash 16.02M 18.38M 12.78M 16.27M 26.25M
Total current liabilities 12.98M 14.17M 16.86M 13.03M 18.76M
Current deferred revenue - - 0.00M 6.21M 1.38M
Net debt -15.12M -17.57M -11.66M -14.91M -24.82M
Short term debt 0.26M 0.41M 0.37M 0.37M 0.37M
Short long term debt total 0.90M 0.81M 1.12M 1.36M 1.43M
Other stockholder equity 361.99M 334.93M 334.49M 289.81M 283.36M
Property plant equipment - - - - 1.68M
Total current assets 53.61M 71.66M 109.56M 97.41M 95.68M
Long term investments 0.24M 3.09M 9.05M 2.90M 27.21M
Net tangible assets - - - - 105.05M
Short term investments 30.42M 34.46M 77.57M 65.54M 57.16M
Net receivables 1.43M 1.74M 3.89M 1.43M 1.28M
Inventory 0.00M 6.90M 11.38M - -
Accounts payable 5.40M 3.41M 5.11M 4.99M 8.57M
Accumulated other comprehensive income 48.54M 51.56M 47.47M 36.64M 30.59M
Non currrent assets other 0.15M 0.25M 0.26M 0.31M 0.34M
Non current assets total 1.58M 4.36M 10.75M 4.99M 29.46M
Capital lease obligations 0.90M 0.81M 1.12M 1.36M 1.43M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 3.35M 52.36M -18.72M 19.36M -25.91M
Change to liabilities - - - - 8.62M
Total cashflows from investing activities 3.11M 52.36M -17.70M - -25.95M
Net borrowings -0.36M -0.39M -0.37M - -0.36M
Total cash from financing activities 32.00M 0.39M 52.99M 1.94M 61.58M
Change to operating activities - - - - -7.08M
Net income -43.83M -46.06M -42.67M -29.48M -45.63M
Change in cash -0.18M 5.61M -3.50M -9.98M 0.28M
Begin period cash flow 16.20M 12.77M 16.27M 26.25M 25.97M
End period cash flow 16.02M 18.38M 12.77M 16.27M 26.25M
Total cash from operating activities -33.92M -48.56M -37.81M -33.74M -39.94M
Issuance of capital stock 22.90M 1.10M 58.83M 2.35M 65.14M
Depreciation 0.40M 0.49M 0.57M 0.60M 0.67M
Other cashflows from investing activities -0.00M 0.00M -0.36M - -
Change to inventory 6.63M 4.47M -11.37M - -
Change to account receivables 2.12M - - - -
Other cashflows from financing activities 0.01M -0.32M -3.12M -0.05M -3.20M
Change to netincome - - - - 3.49M
Capital expenditures 0.11M 0.05M 0.08M 0.16M 0.04M
Change in working capital 4.66M -2.28M 1.00M -9.77M 1.54M
Stock based compensation 4.44M 4.07M 3.41M 6.04M 4.33M
Other non cash items 4.84M -4.76M -0.13M -1.13M -2.00M
Free cash flow -34.03M -48.60M -37.89M -33.91M -39.97M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IFRX
InflaRx N.V.		 -0.04
3.32%		 1.31 - - 9842.62 1.76 6145.05 0.50
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

InflaRx N.V.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Winzerlaer Str. 2, Jena, Germany, 07745

49 3641 508 180

https://www.inflarx.de

65

Name Title Year Born
Dr. Niels C. Riedemann M.D., Ph.D. Co-Founder, CEO & Exec. Director 1972
Prof. Renfeng Guo M.D. Co-Founder, Chief Scientific Officer & Exec. Director 1970
Dr. Thomas Taapken Ph.D. Chief Financial Officer 1965
Ms. Nicole Bertsch Sr. Director & Head of HR NA
Dr. Maria Habel PH.D. Head of Preclinical R&D 1982
Ms. Evelyn Roth-Geissler Ph.D. VP & Head of Clinical Operations NA
Dr. Bruce P. Burnett Ph.D. VP & Head of Medical Affairs NA
Mr. Christian Schmid VP and Head of Legal Affairs & Corp. Counsel NA
Mr. Kafi Boaten Sr. Director and Head of Supply & Clinical Trial Supplies NA
Mr. Peter Hurt Ph.D. Sr. Director and Head of Drug Safety & Pharmacovigiliance NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…